Biomimetic Ca-P coatings incorporating bisphosphonates produced on starch-based degradable biomaterials

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 92, Issue 1, 2010, Pages 55-67

  Oliveira, A L ^a,b   Pedro, A J ^a   Saiz Arroyo, C ^a   Mano, J F ^a   Rodriguez, G ^b   San Roman, J ^b   Reis, R L ^a  

^a UNIVERSITY OF MINHO   (Portugal)

^b INSTITUTO DE CIENCIA Y TECNOLOGÍA DE POLÍMEROS   (Spain)

Author keywords

Biodegradable polymers; Biomimetic coating; Bisphosphonate; Calcium phosphate; Drug therapy; Sodium silicate; Starch

Indexed keywords

BIOMIMETIC COATING; BISPHOSPHONATE; BISPHOSPHONATES; BONE TISSUE REGENERATION; CAP LAYERS; DEGRADABLE BIOMATERIALS; DEGRADABLE POLYMERS; DRUG DELIVERY SYSTEM; OSTEOBLASTIC ACTIVITY; OSTEOBLASTIC CELLS; PRELIMINARY APPROACH; REGENERATIVE EFFECTS; RELEASE PROFILES; SITE-SPECIFIC; SODIUM SILICATE; SPECIFIC CONCENTRATION; STARCH-BASED; STARCH-BASED BIOMATERIALS; STIMULATORY EFFECTS; THERAPEUTIC AGENTS;

BIODEGRADABLE POLYMERS; BIOINFORMATICS; BIOLOGICAL MATERIALS; BIOMATERIALS; BIOMIMETICS; BONE; CALCIUM; CALCIUM ALLOYS; CALCIUM PHOSPHATE; CALCIUM SILICATE; CELL CULTURE; DISSOLUTION; DRUG DELIVERY; FUNCTIONAL POLYMERS; PHOSPHATES; PLASTIC COATINGS; SILICATES; SODIUM; STARCH;

SODIUM SILICATE PROCESS;

BIOMATERIAL; BIOMIMETIC MATERIAL; CALCIUM PHOSPHATE; CLODRONIC ACID; POLYMER; STARCH;

ARTICLE; BIOMIMETICS; BONE DEVELOPMENT; BONE TISSUE; CELL INTERACTION; CELL TYPE; CHEMICAL STRUCTURE; DISSOLUTION; HUMAN; HUMAN CELL; MATERIAL COATING; OSTEOBLAST; TISSUE REGENERATION;

BIOCOMPATIBLE MATERIALS; CALCIUM; CELL ADHESION; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIPHOSPHONATES; HUMANS; MICROSCOPY, ELECTRON, SCANNING; MOLECULAR MIMICRY; OSTEOBLASTS; PHOSPHORUS; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STARCH;

EID: 74749091010     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.31489     Document Type: Article

References (65)

1. Liu Y, De Groot K, Hunziker EB. Osteoinductive implants: The Mise-en-scene for drug-bearing biomimetic coatings. Ann Biomed Eng 2004;32:398-406.
2. Oliveira AL, Mano JF, Reis RL. Nature-inspired calcium phosphate coatings: Present status and novel advances in the science of mimicry. Curr Opin Solid State Mater Sci 2003; 7:309-318.
3. Kohn DH. Metals in medical applications. Curr Opin Solid State Mater Sci 1998;3:309-316.
4. Weng J, Liu Q, Wolke JG, Zhang XD, deGroot K. Formation and characteristics of the apatite layer on plasma-sprayed hydroxyapatite coatings in simulated body fluid. Biomaterials 1997;18:1027-1035.
5. Zheng XB, Huang MH, Ding CX. Bond strength of plasmas-prayed hydroxyapatite/Ti composite coatings. Biomaterials 2000;21:841-849.
6. Gledhill HC, Turner IG, Doyle C. In vitro dissolution behaviour of two morphologically different thermally sprayed hydroxyapatite coatings. Biomaterials 2001;22:695-700.
7. Reis RL, Monteiro FJ. Crystallinity and structural changes in HA plasma-sprayed coatings induced by cyclic loading in physiological media. J Mater Sci: Mater Med 1996;7:407-411.
8. Leonor IB, Kim HM, Balas F, Kawashita M, Reis RL, Kokubo T, Nakamura T. Functionalization of different polymers with sulfonic groups as a way to coat them with a biomimetic apatite layer. J Mater Sci: Mater Med 2007;18:1923-1930.
9. Tuzlakoglu K, Reis RL. Formation of bone-like apatite layer on chitosan fiber mesh scaffolds by a biomimetic spraying process. J Mater Sci: Mater Med 2007;18:1279-1286.
10. Abe Y, Kokubo T, Yamamuro T. Apatite coating on ceramics. Metals and polymers utilizing a biological process. J Mater Sci: Mater Med 1990;1:233-238.
11. Kokubo T, Kushitani H, Sakka S, Kitsugi T, Yamamuro T. Solutions able to reproduce in vivo surface-structure changes in bioactive glass-ceramic A-W. J Biomed Mater Res 1990; 24:721-734.
12. Leonor IB, Azevedo HS, Pashkuleva I, Oliveira AL, Alves CM, Reis RL. Learning from nature how to design biomimetic calcium-phosphate coatings. In: Reis RL, Weiner S, editors. Learning from Nature How to Design New Implantable Biomaterials: From Biomineralization Fundamentals to Biomimetic Materials and Processing Routes. Drodercht: Kluwer Press; 2004. p 123-150.
13. Oliveira AL, Elvira C, Vásquez B, San Roman J, Reis RL. Surface modifications tailors the characteristics of biomimetic coatings nucleated on starch based polymers. J Mater Sci: Mater Med 1999;10:827.
14. Oliveira AL, Leonor IB, Malafaya PB, Alves CM, Azevedo HS, Reis RL. Tailoring the bioactivity of natural origin inorganic-polymeric based systems. Bioceramics 2003;15:240-242.
15. Oliveira AL, Malafaya PB, Reis RL. Sodium silicate gel as a precursor for the in vitro nucleation and growth of a bone-like apatite coating in compact and porous polymeric structures. Biomaterials 2003;24:2575-2584.
16. Nagano M, Nakamura T, Kokubo T, Tanahashi M, Ogawa M. Differences of bone bonding ability and degradation behaviour in vivo between amorphous calcium phosphate and highly crystalline hydroxyapatite coating. Biomaterials 1996; 17:1771-1777.
17. Radin S, Campbell JT, Ducheyne P, Cuckler JM. Calcium phosphate ceramic coatings as carriers of vancomycin. Biomaterials 1997;18:777-782.
18. Campbell AA, Song L, Li XS, Nelson BJ, Bottoni C, Brooks DE, DeJong ES. Development, characterization, and anti-microbial efficacy of hydroxyapatite-chlorhexidine coatings produced by surface-induced mineralization. J Biomed Mater Res 2000;53:400-407.
19. Stigter M, de Groot K, Layrolle P. Incorporation of tobramycin into biomimetic hydroxyapatite coating on titanium. Biomaterials 2002;23:4143-4153.
20. Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA, Kyle RA, Mundy GR, Paterson AH, Rubens RD. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 1998;16:3890-3899.
21. Mastrandrea LD, Albini CH. Bisphosphonate treatment of tumor-induced hypercalcemia in a toddler: Case report and review of related literature. Endocr Pract 2006;12:670-675.
22. Eekhoff ME, Zwinderman AH, Haverkort DM, Cremers SC, Hamdy NA, Papapoulos SE. Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy. Bone 2003;33:831-838.
23. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000;289:1508-1514.
24. Rodan GA, Fleisch HA. Bisphosphonates: Mechanisms of action. J Clin Invest 1996;97:2692-2696.
25. Fleisch H. Bisphosphonates: Mechanisms of action. Expert Opin Ther Patents 2001;11:1371-1381.
26. Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 2000;42:175-195.
27. Henneman ZJ, Nancollas GH, Ebetino FH, Russell RG, Phipps RJ. Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro. J Biomed Mater Res A 2008;85:993-1000.
28. Fisher JE, Rodan GA, Reszka AA. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 2000;141:4793-4796.
29. Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugal N, Yamamoto M, Nagata N. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 1996;18:9-14.
30. Adami S, Zamberlan N. Adverse effects of bisphosphonates - A comparative review. Drug Safety 1996;14:158-170.
31. Sutton SC, Engle K, Fix JA. Intranasal delivery of the bisphosphonate alendronate in the rat and dog. Pharm Res 1993;10:924-926.
32. Duncan AR. The use of subcutaneous pamidronate. J Pain Symptom Manage 2003;26:592-593.
33. Osterman T, Lauren L. Level of clodronate in bone after single and repeated subcutaneous injections in rats. Pharmacol Toxicol 1991;69:369-371.
34. Walker P, Watanabe S, Lawlor P, Hanson J, Pereira J, Bruera E. Subcutaneous clodronate: A study evaluating efficacy in hypercalcemia of malignancy and local toxicity. Ann Oncol 1997;8:915-916.
35. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004;9(suppl 4):28-37.
36. Venesmaa PK, Kröger HP, Miettinen HJ, Jurvelin JS, Suomalainen OT, Alhav EM. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: A prospective randomized study. J Bone Miner Res 2001; 16:2126-2131.
37. Nehme A, Maalouf G, Tricoire JL, Giordano G, Chiron P, Puget J. Effect of alendronate on periprosthetic bone loss after cemented primary total hip arthroplasty: A prospective randomized study. Revue De Chirurgie Orthopedique Et Reparatrice De L Appareil Moteur 2003;89:593-598.
38. Yamaguchi K, Masuhara K, Yamasaki S, Nakai T, Fuji T. Cyclic therapy with etidronate has a therapeutic effect against local osteoporosis after cementless total hip arthroplasty. Bone 2003;33:144-149.
39. Venesmaa PK, Kröger HP, Miettinen HJ, Jurvelin JS, Suomalainen OT, Alhava EM. Monitoring of periprosthetic BMD after uncemented total hip arthroplasty with dual-energy Xray absorptiometry-a 3-year follow-up study. J Bone Miner Res 2001;16:1056-1061.
40. Kajiwara H, Yamaza T, Yoshinari M, Goto T, Iyama S, Atsuta I, Kido MA, Tanaka T. The bisphosphonate pamidronate on the surface of titanium stimulates bone formation around tibial implants in rats. Biomaterials 2005;26:581-587.
41. Yoshinari M, Oda Y, Inoue T, Matsuzaka K, Shimono M. Bone response to calcium phosphate-coated and bisphosphonate-immobilized titanium implants. Biomaterials 2002;23: 2879-2885.
42. Peter B, Pioletti DP, Laib S, Bujoli B, Pilet P, Janvier P, Guicheux J, Zambelli PY, Bouler JM, Gauthier O. Calcium phosphate drug delivery system: Influence of local zoledronate release on bone implant osteointegration. Bone 2005; 36:52-60.
43. Reis RL, Cunha AM. Characterization of two biodegradable polymers of potential application within the biomaterials field. J Mater Sci: Mater Med 1995;6:786-792.
44. Reis RL, Cunha AM, Allan PS, Bevis MJ. Mechanical behavior of injection-molded starch-based polymers. Polym Adv Technol 1996;7:784-790.
45. Sousa RA, Reis RL, Cunha AM, Bevis MJ. Processing and properties of bone-analogue biodegradable and bioinert polymeric composites. Compos Sci Technol 2003;63:389-402.
46. Reis RL, Mendes SC, Cunha AM, Bevis MJ. Processing and in vitro degradation of starch/EVOH thermoplastic blends. Polym Int 1997;43:347-352.
47. Oliveira AL, Malafaya PB, Costa SA, Sousa RA, Reis RL. Micro-computed tomography (mu-CT) as a potential tool to assess the effect of dynamic coating routes on the formation of biomimetic apatite layers on 3D-plotted biodegradable polymeric scaffolds. J Mater Sci: Mater Med 2007;18:211-223.
48. Plosker GL, Goa KL. Clodronate - A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1994;47:945-982.
49. Oliveira AL, Santos MI, Pedro AA, Reis RL. Bisphosphonates incorporated on a Ca-P biomimetic coating produced by a sodium silicate based methodology stimulate osteoblastic activity. Bioceramics 2005;17:615-618.
50. Azevedo HS, Gama FM, Reis RL. In vitro assessment of the enzymatic degradation of several starch based biomaterials. Biomacromolecules 2003;4:1703-1712.
51. Reis RL, Cunha AM. Characterization of two biodegradable polymers of potential application within the biomaterials field. J Mater Sci: Mater Med 1995;6:786-792.
52. Rehman I, Bonfield W. Characterization of hydroxyapatite and carbonated apatite by photo acoustic FTIR spectroscopy. J Mater Sci: Mater Med 1997;8:1-4.
53. Oliveira AL, Malafaya PB, Reis RL. Sodium silicate gel induced self-mineralization of different compact and porous polymeric structures. Bioceramics 2000;192:75-78.
54. Budz JA, Nancollas GH. The mechanism of dissolution of hydroxyapatite and carbonated apatite in acidic solutions. J Cryst Growth 1988;91:490-496.
55. Ducheyne P, Radin S, King L. The effect of calcium-phosphate ceramic composition and structure on in vitro behavior. I. Dissolution. J Biomed Mater Res 1993;27:25-34.
56. Zhang Q, Chen J, Feng J, Cao Y, Deng C, Zhang X. Dissolution and mineralization behaviors of HA coatings. Biomaterials 2003;24:4741-4748.
57. Matsuoka H, Nakamura T, Takadama H, Yamada S, Tamura J, Okada Y, Oka M, Kokubo T. Osteoclastic resorption of bone-like apatite formed on a plastic disk as an in vitro assay system. J Biomed Mater Res 1998;42:278-285.
58. Oliveira AL, Reis RL. Pre-mineralisation of starch/polycrapolactone bone tissue engineering scaffolds by a calciumsilicate-based process. J Mater Sci: Mater Med 2004;15:533-540.
59. Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 2000;42:175-195.
60. Seshima H, Yoshinari M, Takemoto S, Hattori M, Kawada E, Inoue T, Oda Y. Control of bisphosphonate release using hydroxyapatite granules. J Biomed Mater Res B Appl Biomater 2006;78:215-221.
61. Josse S, Faucheux C, Soueidan A, Grimandi G, Massiot D, Alonso B, Janvier P, Laib S, Pilet P, Gauthier O. Novel biomaterials for bisphosphonate delivery. Biomaterials 2005;26: 2073.
62. Yoshinari M, Oda Y, Ueki H, Yokose S. Immobilization of bisphosphonates on surface modified titanium. Biomaterials 2001;22:709-715.
63. Peter B, Gauthier O, Laib S, Bujoli B, Guicheux J, Janvier P, van Lenthe GH, Muller R, Zambelli PY, Bouler JM, Pioletti DP. Local delivery of bisphosphonate from coated orthopedic implants increases implants mechanical stability in osteoporotic rats. J Biomed Mater Res 2006;76:133-143.
64. Kontturi M, Peraniemi S, Vepsalainen JJ, Ahlgren M. X-ray diffraction study of bisphosphonate metal complexes: Mg and Ca complexes of (dichloromethylene)bisphosphonic acid P,P′-diisopropyl ester. Polyhedron 2005;24:305.
65. Ganguli A, Henderson C, Grant MH, Meikle ST, Lloyd AW, Goldie I. The interactions of bisphosphonates in solution and as coatings on hydroxyapatite with osteoblasts. J Mater Sci: Mater Med 2002;13:923-931.